A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

被引：0
|
作者：
J. Devine
S. Trice
Z. Finney
S. Yarger
E. Nwokeji
A. Linton
W. Davies
机构：
[1] TRICARE Management Activity (TMA),
[2] Pharmacoeconomic Center,undefined
[3] TRICARE Management Activity (TMA),undefined
[4] Pharmacy Operations Directorate,undefined
来源：
Osteoporosis International | 2012年 / 23卷
关键词：
Adherence; Bisphosphonate; Compliance; Osteoporosis; Persistence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1415 / 1424
页数：9
相关论文
共 44 条
  • [1] A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System
    Devine, J.
    Trice, S.
    Finney, Z.
    Yarger, S.
    Nwokeji, E.
    Linton, A.
    Davies, W.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 (04) : 1415 - 1424
  • [2] Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
    Bryant, Alex K.
    Lewy, Jacqueline R.
    Bressler, R. Daniel
    Chopra, Zoey
    Gyori, Derek J.
    Bazzell, Brian G.
    Moeller, Julie A.
    Jacobson, Sofia, I
    Fendrick, A. Mark
    Kerr, Eve A.
    Ramnath, Nithya
    Green, Michael D.
    Hofer, Timothy P.
    Vaishnav, Parth
    Strohbehn, Garth W.
    [J]. LANCET ONCOLOGY, 2024, 25 (06): : 802 - 810
  • [3] A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
    Bailey, TC
    Little, JR
    Littenberg, B
    Reichley, RM
    Dunagan, WC
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) : 786 - 795
  • [4] Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
    Goldstein, Daniel A.
    Ginsberg, Gary M.
    Hofnung-Gabbay, Dorit
    Lourenco, Richard De Abreu
    Loong, Herbert H.
    Goh, Boon Cher
    Chan, Kelvin K. W.
    Di Maio, Massimo
    Perrone, Francesco
    Hall, Peter S.
    Zer, Alona
    Rosenbaum, Eli
    [J]. JAMA NETWORK OPEN, 2023, 6 (02) : E230490
  • [5] Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in US patients with unresectable stage III NSCLC following concurrent chemoradiation
    Haque, R.
    McGary, E.
    Yang, M.
    Liu, R.
    Suga, J. M.
    Chen, L. H.
    Zhu, Z.
    Simmons, D.
    Hsieh, K.
    Cotarla, I.
    Sakoda, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E50 - E50
  • [6] A Case for Telestroke in Military Medicine: A Retrospective Analysis of Stroke Cost and Outcomes in US Military Health-Care System
    Dave, Ajal
    Cagniart, Kendra
    Holtkamp, Matthew D.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (08): : 2277 - 2284
  • [7] A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan
    Ito, Takamichi
    Kaku-Ito, Yumiko
    Ohno, Fumitaka
    Nakahara, Takeshi
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [8] An international comparison of the impact of dosing frequency on compliance and persistence with bisphosphonate therapy, among post-menopausal women in the US, UK and Germany
    Cramer, JA
    Lynch, NO
    Walker, M
    Cowell, W
    Suppapanya, N
    Rigney, U
    Hammerschmidt, T
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A138 - A138
  • [9] Prevalence and Characteristics of CKD in the US Military Health System: A Retrospective Cohort Study
    Oliver, James D., III
    Nee, Robert
    Grunwald, Lindsay R.
    Banaag, Amanda
    Pavkov, Meda E.
    Burrows, Nilka Rios
    Koehlmoos, Tracey Perez
    Marks, Eric S.
    [J]. KIDNEY MEDICINE, 2022, 4 (07)
  • [10] A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation
    Downes, Kevin J.
    Grim, Austyn
    Shanley, Laura
    Rubenstein, Ronald C.
    Zuppa, Athena F.
    Gastonguay, Marc R.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (05)
12345